Mylan has head start on US Adcirca rival
Mylan has strengthened the firm’s cardiovascular portfolio in the US by launching the first generic of Eli Lilly’s Adcirca (tadalafil) 20mg tablets with 180 days of marketing exclusivity. The launch comes shortly after Mylan received final approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) referencing the treatment for pulmonary arterial hypertension to improve exercise ability.
You may also be interested in...
Mylan is pushing ahead with reforms that include wide-ranging product rationalization in the US, refocusing its commercial resources and cutting development and manufacturing costs. These reforms are intended to run prior to and concurrently with the group’s merger with Pfizer’s Upjohn unit to form Viatris.
Multiple generic versions of Eli Lilly’s Cialis (tadalafil) tablets have been launched in the US, following the expiry of Teva’s 180-day exclusivity. The Israeli company introduced its first-to-file version of its Cialis rival in September 2018; now a number of firms have obtained approval, while others have launched generic alternatives.
Teva has introduced the first generic version of Lundbeck’s Sabril 500mg tablets in the US, less than a month after obtaining FDA approval for the drug.